The Effect of Omega-3 Supplement on Serum Lipid Profile in Patients Undergoing Hemodialysis: A Randomized Clinical Trial

1. SENTÍM, ROMERO R, PEDRO-BOTET J, PELEGRÍA, NOGUÉS X, RUBIÉS-PRAT J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992; 41:1394.10.1038/ki.1992.204Search in Google Scholar

2. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21:573.10.1016/S0272-6386(12)80030-8Search in Google Scholar

3. ARNADOTTIR M, THYSELL H, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 1995; 48:779.10.1038/ki.1995.350Search in Google Scholar

4. LACOUR B, ROULLET JB, LIAGRE AM, JORGETTI V, BEYNE P, DUBOST C, DRÜEKE T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8:422.10.1016/S0272-6386(86)80169-XSearch in Google Scholar

5. LIANG K, OVEISI F, VAZIRI ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998; 53:626.10.1046/j.1523-1755.1998.00786.xSearch in Google Scholar

6. AKMAL M, PERKINS S, KASIM SE, OH HY, SMOGORZEWSKI M, MASSRY SG. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis. 1993; 22:158.10.1016/S0272-6386(12)70182-8Search in Google Scholar

7. CHEUNG AK, PARKER CJ, REN K, IVERIUS PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996; 49:1360.10.1038/ki.1996.1928731101Search in Google Scholar

8. KRIS-ETHERTON PM, HARRIS WS, APPEL LJ, et al. American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106:2747-2757.10.1161/01.CIR.0000038493.65177.94Search in Google Scholar

9. SERHAN CN, HONG S, GRONERT K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med.2002;196: 1025-1037.10.1084/jem.20020760219403612391014Search in Google Scholar

10. HARRIS WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr. 1997; 65:1645S-1654S.10.1093/ajcn/65.5.1645S9129504Search in Google Scholar

11. ERITSLAND J, ARNESEN H, GRONSETH K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996; 77:31-36.10.1016/S0002-9149(97)89130-8Search in Google Scholar

12. THIES F, GARRY JM, YAQOOB P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003; 361:477-485.10.1016/S0140-6736(03)12468-3Search in Google Scholar

13. FRIEDMAN AN, MOE SM, PERKINS SM, et al. Fish consumption and omega-3 fatty acid status and determinants in longterm hemodialysis. J Am Kidney Dis 2006:1064-1071.10.1053/j.ajkd.2006.03.03316731302Search in Google Scholar

14. FRIEDMAN AN, SIDDIQUI R, WATKINS BA. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008; 18(3):301-3.10.1053/j.jrn.2007.11.002238695218410887Search in Google Scholar

15. OMRANI HR, PASDAR Y, RAISI D, NAJAFI F, ESFANDIARI A. The effect of omega-3 on serum lipid profile in hemodialysis patients. J Renal Inj Prev. 2015; 4:68-72.Search in Google Scholar

16. TAZIKI O, LESSAN-PEZESHKI M, AKHA O, VASHEGHANI F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007; 18(4):571-6.Search in Google Scholar

17. HASSAN KS, HASSAN SK, HIJAZI EG, KHAZIM KO. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail. 2010; 32:1031-5.10.3109/0886022X.2010.51023120863205Search in Google Scholar

18. BAYS HE, TIGHE AP, SADOVSKY R, DAVIDSON MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc. Ther. 2008; 6:391-409.Search in Google Scholar

19. HARRIS WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr 1997; 65:S1645-54.10.1093/ajcn/65.5.1645S9129504Search in Google Scholar

20. LAPUZ M, AVRAM MM, LUSTIG A, GOLDWASSER P, ANTIGNANI A, FEIN PA, et al. Fall of cholesterol with time on dialysis: impact on atherogenicity. ASAIO Trans. 1989; 35:258-60.10.1097/00002216-198907000-00026Search in Google Scholar

21. CHI H, LIN X, HUANG H, ZHENG X, LI T, ZOU Y. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014; 45:469-77.10.1016/j.arcmed.2014.06.00825010561Search in Google Scholar

22. ASHTIYANI SC, NAJAFI H, KABIRINIA K, VAHEDI E, JAMEBOZORKYL. Oral omega-3 fatty acid for reduction of kidney dysfunction induced by reperfusion injury in rats. Iran J Kidney Dis. 2012; 6:275-83.Search in Google Scholar

23. HOLM T, ANDREASSEN AK, AUKRUST P, ANDERSEN K, GEIRAN OR, KJEKSHUS J, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 2001; 22:428-36.10.1053/euhj.2000.236911207085Search in Google Scholar